Pharma Companies Get On Board With Regeneron To Speed Biobank Sequencing
AbbVie, Alnylam, AstraZeneca and Pfizer join forces with Regeneron to speed up the sequencing of the 500,000 genetic samples in the UK's Biobank.
You may also be interested in...
Regeneron advocates industry-FDA collaboration to establish regulatory standards for novel applications of genomic data, such as determining whether long-term outcomes studies are needed, and inclusion of the data in product labeling.
AstraZeneca has entered into a series of early research collaborations in a bid to integrate genomics into the foundations of its entire drug discovery and development infrastructure.
A Phase III rare-disease hit for Sanofi marks the first of a number of orphan drug read-outs expected in the coming year.